文献速递泌尿生殖介入MR

MRI引导经直肠前列腺激光消融治疗良性前列腺增生:一项回顾性队列研究

MRI-guided transrectal prostate laser ablation for benign prostatic hypertrophy: a retrospective cohort study.
PubMed 文献 · Radiol Med · 2024-08-18

该单中心回顾性队列研究纳入52例接受MRI引导经直肠激光消融治疗BPH相关下尿路症状的男性,评估IPSS与SHIM变化及不良事件。消融后6、12、24个月IPSS较基线平均下降16.7、16.9、17.1分(均p<0.001),SHIM各时间点升高无统计学意义,19例(36.5%)出现并发症,无III级及以上并发症。作者认为该技术安全有效。

要点

  • 消融后24个月IPSS较基线平均下降17.1分(p<0.001)。
  • 19例(36.5%)报告并发症,均为I级(13.5%)或II级(23%)。
  • 曾接受BPH手术者与未接受者IPSS下降无显著差异(p=0.628)。

核心结论

  • 经直肠MRI引导局灶激光消融对BPH所致下尿路症状安全有效,2年后症状严重程度显著改善。

研究设计与样本

  • 单中心回顾性队列研究,纳入2017年2月至2021年7月接受MRI引导经直肠激光消融的BPH男性52例,至少完成一次随访调查。

诊断标准与关键数值

  • IPSS较基线在6、12、24个月分别平均下降16.7±7.0分、16.9±7.5分、17.1±7.2分(均p<0.001)。
  • 曾接受BPH手术者与未接受者IPSS下降无统计学显著差异(p=0.628)。
  • SHIM评分各时间点升高无统计学意义。
  • 并发症19例(36.5%):II级12例(23%),I级7例(13.5%),无III级及以上并发症。

局限性

  • 单中心回顾性队列研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To investigate whether MRI-guided transrectal laser ablation is safe and effective for the treatment of lower urinary tract symptoms caused by BPH.

MATERIALS AND METHODS: This single-center retrospective cohort study evaluated men who underwent MRI-guided transrectal laser ablation for BPH between February 2017 and July 2021. Age, prostate-specific antigen, prostate volume, prior surgical BPH treatments if any, International Prostate Symptom Score (IPSS) and Sexual Health Inventory of Men (SHIM) were collected. The primary outcome measures assessed were change in IPSS and SHIM 6, 12 and 24 months after laser ablation and adverse events.

RESULTS: Fifty-two patients were included, having completed at least one follow-up survey. The mean patient age was 62.9 ± 5.7 years, and mean prostate volume was 80.2 ± 39.2 cc. Eighteen patients (34.6%) had received a prior BPH treatment. The IPSS scores dropped an average of 16.7 ± 7.0 (p < 0.001), 16.9 ± 7.5 (p < 0.001) and 17.1 ± 7.2 (p < 0.001) points from baseline at 6, 12 and 24 months, respectively. There was no statistically significant difference in IPSS score drop between patients who had received a prior BPH procedure and those who had not (p = 0.628). The SHIM scores showed a statistically insignificant increase at all time points. Nineteen patients (36.5%) reported a complication. There were 12 grade II complications (23%) and seven grade I complications (13.5%). There were no grade III or higher complications.

CONCLUSION: Transrectal MRI-guided focal laser ablation is safe and effective for the treatment of lower urinary tract symptoms caused by BPH, with a significant improvement in symptom severity after 2 years.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Harman A, Toth R, Mobley Z, et al. MRI-guided transrectal prostate laser ablation for benign prostatic hypertrophy: a retrospective cohort study. Radiol Med. 2024. PMID: 39154318. doi:10.1007/s11547-024-01855-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。